Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03355235 · ClinicalTrials.gov registry record
Brilliant Study: Assessing Cognition in Myeloma Patients Undergoing Transplant
A clinical trial of Stem Cell Transplant Complications, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT03355235 is a study of Stem Cell Transplant Complications that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 50 participants, below the 182-participant average among 15 other Stem Cell Transplant Complications trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03355235, a study of Stem Cell Transplant Complications, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall objectives in this study are to identify patterns of cognitive impairment pre- and post-transplant, to assess the similarities of scores of the three cognitive assessments in myeloma patients who undergo autologous stem cell transplant, and to determine if patients prefer the self-assessment, Self-Administered Gerocognitive Exam (SAGE) or the healthcare applied Montreal Cognitive Assessment (MoCA) assessment.
Conditions Studied
Study Locations (1)
North Carolina
- Wake Forest University Health Sciences - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2017-10-20 |
| Est. Completion | 2019-08-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03355235
The ClinicalTrials.gov registry entry for NCT03355235 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 182-participant average among 15 other Stem Cell Transplant Complications trials with a reported enrollment target (73% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Stem Cell Transplant Complications appearing as the primary indexed condition, and to 0 interventions.
NCT03355235 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT03355235 about?
NCT03355235 is a clinical study titled "Brilliant Study: Assessing Cognition in Myeloma Patients Undergoing Transplant". The overall objectives in this study are to identify patterns of cognitive impairment pre- and post-transplant, to assess the similarities of scores of the three cognitive assessments in myeloma patients who undergo autologous stem cell transplant, and to determine if patients prefer the self-assess...
What is the current status of trial NCT03355235?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2017-10-20. Estimated completion is 2019-08-27.
What conditions does trial NCT03355235 study?
This clinical trial studies the following conditions: Stem Cell Transplant Complications.
Who is sponsoring clinical trial NCT03355235?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03355235 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stem Cell Transplant Complications
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant Survivors
RECRUITING · NA
-
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
RECRUITING · Phase 2
-
Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
RECRUITING · NA
-
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
RECRUITING · Phase 3
-
Intestinal Microbiota in Stem Cell Transplant Transplant Admission
RECRUITING
-
IS-free Treg HaploHCT
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.